Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors

Capital World Investors decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,434,253 shares of the biopharmaceutical company’s stock after selling 370,754 shares during the period. Alnylam Pharmaceuticals makes up 1.0% of Capital World Investors’ portfolio, making the stock its 20th biggest position. Capital World Investors owned about 12.44% of Alnylam Pharmaceuticals worth $7,493,808,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Capital International Sarl increased its stake in shares of Alnylam Pharmaceuticals by 1.1% during the third quarter. Capital International Sarl now owns 129,702 shares of the biopharmaceutical company’s stock valued at $59,144,000 after acquiring an additional 1,416 shares during the period. Capital International Inc. CA boosted its stake in Alnylam Pharmaceuticals by 5.3% during the 3rd quarter. Capital International Inc. CA now owns 75,638 shares of the biopharmaceutical company’s stock valued at $34,491,000 after purchasing an additional 3,807 shares in the last quarter. Capital International Investors acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $246,000. Legal & General Group Plc raised its stake in shares of Alnylam Pharmaceuticals by 1.7% in the 3rd quarter. Legal & General Group Plc now owns 887,780 shares of the biopharmaceutical company’s stock worth $404,828,000 after buying an additional 15,009 shares in the last quarter. Finally, Pinkerton Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $934,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research analyst reports. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. HC Wainwright restated a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. Needham & Company LLC lowered their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Finally, Chardan Capital decreased their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer directly owned 78,411 shares in the company, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.9%

ALNY stock opened at $323.53 on Tuesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm has a market capitalization of $42.91 billion, a P/E ratio of 189.20 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company’s 50 day simple moving average is $350.74 and its 200-day simple moving average is $413.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.65) earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.